Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher William West is active.

Publication


Featured researches published by Christopher William West.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels

Ken McCormack; Sonia Santos; Mark L. Chapman; Douglas S. Krafte; Brian Edward Marron; Christopher William West; Michael J. Krambis; Brett M. Antonio; Shannon Zellmer; David Printzenhoff; Karen Padilla; Zhixin Lin; P. Kay Wagoner; Nigel Alan Swain; Paul Anthony Stupple; Marcel J. de Groot; Richard P. Butt; Neil A. Castle

Significance Voltage-gated sodium (Nav) channels contribute to physiological and pathophysiological electrical signaling in nerve and muscle cells. Because Nav channel isoforms exhibit tissue-specific expression, subtype selective modulation of this channel family provides important drug development opportunities. However, most available Nav channel modulators are unable to distinguish between Nav channel subtypes, which limits their therapeutic utility because of cardiac or nervous system toxicity. This study describes a new class of subtype selective Nav channel inhibitors that interact with a region of the channel that controls voltage sensitivity. This interaction site may enable development of selective therapeutic interventions with reduced potential for toxicity. Voltage-gated sodium (Nav) channels play a fundamental role in the generation and propagation of electrical impulses in excitable cells. Here we describe two unique structurally related nanomolar potent small molecule Nav channel inhibitors that exhibit up to 1,000-fold selectivity for human Nav1.3/Nav1.1 (ICA-121431, IC50, 19 nM) or Nav1.7 (PF-04856264, IC50, 28 nM) vs. other TTX-sensitive or resistant (i.e., Nav1.5) sodium channels. Using both chimeras and single point mutations, we demonstrate that this unique class of sodium channel inhibitor interacts with the S1–S4 voltage sensor segment of homologous Domain 4. Amino acid residues in the “extracellular” facing regions of the S2 and S3 transmembrane segments of Nav1.3 and Nav1.7 seem to be major determinants of Nav subtype selectivity and to confer differences in species sensitivity to these inhibitors. The unique interaction region on the Domain 4 voltage sensor segment is distinct from the structural domains forming the channel pore, as well as previously characterized interaction sites for other small molecule inhibitors, including local anesthetics and TTX. However, this interaction region does include at least one amino acid residue [E1559 (Nav1.3)/D1586 (Nav1.7)] that is important for Site 3 α-scorpion and anemone polypeptide toxin modulators of Nav channel inactivation. The present study provides a potential framework for identifying subtype selective small molecule sodium channel inhibitors targeting interaction sites away from the pore region.


Journal of Medicinal Chemistry | 2017

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

Nigel Alan Swain; Dave Batchelor; Serge Beaudoin; Bruce M. Bechle; Paul Anthony Bradley; Alan Daniel Brown; Bruce Brown; Kenneth John Butcher; Richard P. Butt; Mark L. Chapman; Stephen Martin Denton; David Ellis; Sebastien Rene Gabriel Galan; Stephen M Gaulier; Ben S. Greener; Marcel J. de Groot; Mel S Glossop; Ian Gurrell; Jo Hannam; Matthew S. Johnson; Zhixin Lin; Christopher John Markworth; Brian Edward Marron; David Simon Millan; Shoko Nakagawa; Andy Pike; David Printzenhoff; David James Rawson; Sarah J Ransley; Steven Reister

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.


ACS Medicinal Chemistry Letters | 2017

Discovery of a Series of Indazole TRPA1 Antagonists

David C. Pryde; Brian Edward Marron; Christopher William West; Steven Reister; George S. Amato; Katrina Yoger; Brett Antonio; Karen Padilla; Peter J. Cox; Jamie Turner; Joseph Scott Warmus; Nigel Alan Swain; Kiyoyuki Omoto; John H. Mahoney; Aaron C. Gerlach

A series of TRPA1 antagonists is described which has as its core structure an indazole moiety. The physical properties and in vitro DMPK profiles are discussed. Good in vivo exposure was obtained with several analogs, allowing efficacy to be assessed in rodent models of inflammatory pain. Two compounds showed significant activity in these models when administered either systemically or topically. Protein chimeras were constructed to indicate compounds from the series bound in the S5 region of the channel, and a computational docking model was used to propose a binding mode for example compounds.


Archive | 2013

Benziimidazole and imidazopyridine derivatives as sodium channel modulators

Sharanjeet Kaur Bagal; Alan Daniel Brown; Mark Ian Kemp; Wolfgang Klute; Brian Edward Marron; Duncan Charles Miller; Sarah Elizabeth Skerratt; Mark J. Suto; Christopher William West; Sanz Laia Malet


Archive | 2016

N-(2-ALKYLENEIMINO-3-PHENYLPROPYL)ACETAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND PRURITUS VIA INHIBITION OF TRPA1 CHANNELS

Nigel Alan Swain; David C. Pryde; David James Rawson; Thomas Ryckmans; Sarah Elizabeth Skerratt; George S. Amato; Brian Edward Marron; Steven Reister; Christopher William West


Archive | 2011

Bencenosulfonamidas útiles como inhibidores de los canales de sodio

Alan Daniel Brown; Groot Marcel John De; Brian Edward Marron; David James Rawson; Thomas Ryckmans; Robert Ian Storer; Paul Anthony Stupple; Nigel Alan Swain; Christopher William West


Archive | 2011

Sulfonamide nav1.7 inhibitors

Christopher John Markworth; Brian Edward Marron; David James Rawson; Robert Ian Storer; Nigel Alan Swain; Christopher William West; Shulan Zhou


Archive | 2011

Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques

Alan Daniel Brown; Groot Marcel John De; Brian Edward Marron; David James Rawson; Thomas Ryckmans; Robert Ian Storer; Paul Anthony Stupple; Nigel Alan Swain; Christopher William West


Archive | 2011

Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors

Alan Daniel Brown; Groot Marcel John De; Brian Edward Marron; David James Rawson; Thomas Ryckmans; Robert Ian Storer; Paul Anthony Stupple; Nigel Alan Swain; Christopher William West


Archive | 2011

Inhibiteurs de nav1.7 de type sulfonamide

Christopher John Markworth; Brian Edward Marron; David James Rawson; Robert Ian Storer; Nigel Alan Swain; Christopher William West; Shulan Zhou

Collaboration


Dive into the Christopher William West's collaboration.

Researchain Logo
Decentralizing Knowledge